Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price was up 0.8% during trading on Monday . The stock traded as high as $25.98 and last traded at $25.92. Approximately 8,257,993 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 39,173,918 shares. The stock had previously closed at $25.72.
Analysts Set New Price Targets
Several equities analysts have commented on PFE shares. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday. Citigroup dropped their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, StockNews.com downgraded Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $31.92.
View Our Latest Stock Analysis on PFE
Pfizer Trading Down 0.2 %
The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a fifty day moving average of $26.18 and a two-hundred day moving average of $27.07. The stock has a market capitalization of $148.29 billion, a price-to-earnings ratio of 18.56, a P/E/G ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the company earned $0.10 earnings per share. The company's revenue for the quarter was up 24.7% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.
Insider Buying and Selling at Pfizer
In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Pfizer
Hedge funds and other institutional investors have recently bought and sold shares of the business. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $26,000. Clarity Asset Management Inc. purchased a new position in shares of Pfizer in the fourth quarter valued at $27,000. Gould Capital LLC increased its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $28,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Company Profile
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
